ReviewWorld journal of clinical cases2019
Current status of the adjuvant therapy in uterine sarcoma: A literature review.
Review in World journal of clinical cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Combination of immune checkpoint inhibitors and anthracyclines as a potential first-line regimen for dedifferentiated liposarcoma: systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2025Pooled it
- A novel nomogram for predicting cancer-specific survival in women with uterine sarcoma: a large population-based study.BMC women's health · 2022Trial
- Evaluation of surgical approach and adjuvant therapy in uterine sarcomas: an 11-year population-based study.BMC cancer · 2026Article
- When Local Beats Systemic: Durable Control of Metastatic Undifferentiated Uterine Sarcoma and Surveillance Uncovering a Second Primary.Acta medica Lituanica · 2026Article
- Article
- Metachronous head and neck osteosarcoma in an elderly patient: A rare case report with prior verrucous carcinoma.Medicine · 2025Article
- Review
- Core needle biopsy of periacetabular chondrosarcoma often results in undergrading but does not change management by experienced orthopaedic oncologists.Scientific reports · 2025Article
- Uterine Spindle Cell Sarcoma Presenting With Lower Gastrointestinal Bleeding: A Case Report.Cureus · 2025Article
- Dual Targeting EZH2 and Histone Deacetylases in Human Uterine Sarcoma Cells Under Both 2D and 3D Culture Conditions.Journal of cellular and molecular medicine · 2025Article
- Feasibility of machine learning-based modeling and prediction to assess osteosarcoma outcomes.Scientific reports · 2025Article
- Article
- Genetic profiling of osteosarcoma in an adolescent using a next‑generation sequencing panel and Sanger sequencing: A case report and review of the literature.Biomedical reports · 2025Article
- BCOR abnormalities in endometrial stromal sarcoma.Gynecologic oncology reports · 2025Review
- Establishment and validation of a nomogram model for predicting early death in patients with endometrial cancer bone metastases.Frontiers in oncology · 2025Article
- Case Report: A rare case of bilateral primary Müllerian adenosarcoma of the ovary with Uncommon extensive metastasis andFrontiers in oncology · 2025Article
- Article
- Article
- Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).International journal of oncology · 2024Review
- A promising response of refractory uterine leiomyosarcoma to pembrolizumab and temozolomide combination therapy.Gynecologic oncology reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine sarcomas (US) are rare mesenchymal tumours accounting approximately for 3%-7% of all uterine cancers. Histologically, US are classified into mesenchymal tumours or mixed epithelial and mesenchymal tumours. The group of mesenchymal tumours includes uterine leiomyosarcoma (uLMS, 65% of cases), endometrial stromal sarcoma (ESS, 21%) - traditionally divided into low grade (LG-ESS) and high grade-undifferentiated uterine sarcoma (5%) and other rare subtypes such as alveolar or embryonal rhabdomyosarcoma. Despite the fact that several drugs demonstrated clinical activity in advanced or metastatic settings, the role of postoperative therapy in US remains controversial. In this review, we have summarised the current state of the art, including the chief trials on adjuvant treatment modalities in US, especially focusing on uLMS, LG-ESS and other rare histotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.